Title: Risk of Clostridioides difficile infection in inflammatory bowel disease patients
undergoing vedolizumab treatment: a systematic review and meta-analysis
Version: 3 Date: 15 Aug 2024
Reviewer's report:
Please discuss if there was any effect if vedolizumab was used as first, second or even third
line treatment.
Please discuss other co-existing risk factors for CDI infection.
Title: Risk of Clostridioides difficile infection in inflammatory bowel disease patients
undergoing vedolizumab treatment: a systematic review and meta-analysis
Version: 3 Date: 15 Aug 2024
Reviewer's report:
Please discuss if there was any effect if vedolizumab was used as first, second or even third
line treatment.
Please discuss other co-existing risk factors for CDI infection.
Please review this paper.
user
Title: Risk of Clostridioides difficile infection in inflammatory bowel disease patients
undergoing vedolizumab treatment: a systematic review and meta-analysis
Version: 3 Date: 15 Aug 2024
Reviewer's report:
Please discuss if there was any effect if vedolizumab was used as first, second or even third
line treatment.
Please discuss other co-existing risk factors for CDI infection.
assistant